Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study - Janni, Wolfgang; Wischnik, Arthur (British journal of cancer, 2016)
Gesehen am 05.11.2019